IKAROS family zinc finger 1/IKZF1 is a transcription factor important in lymphoid differentiation, and a known tumor suppressor in acute lymphoid leukemia. Recent studies suggest that IKZF1 is also involved in myeloid differentiation. To investigate whether IKZF1 deletions also play a role in pediatric acute myeloid leukemia, we screened a panel of pediatric acute myeloid leukemia samples for deletions of the IKZF1 locus using multiplex ligation-dependent probe amplification and for mutations using directsequencing. Three patients were identified with a single amino acid variant without change of IKZF1 length. No frame-shift mutations were found. Out of 11 patients with an IKZF1 deletion, eight samples revealed a complete loss of chromosome 7, and three cases a focal deletion of 0.1-0.9Mb. These deletions included the complete IKZF1 gene (n=2) or exons 1-4 (n=1), both leading to a loss of IKZF1-function.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by dysregulated hematopoiesis initiated by recurrent non-random genetic aberrations.
1, 2 Despite major progress in improving treatment over the past decades, AML remains a life-threatening malignancy in children. The 5 year event-free survival (EFS) rates of pediatric AML are currently ~50-60% and the overall survival (OS) rate ~70%.
3, 4
Treatment stratification is mainly based on early response to treatment and prognostic relevant genetic abnormalities. Although many driving recurrent genetic aberrations causing AML have been defined, in approximately 20% of the pediatric AML patients the driving genetic events remain unidentified.
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The DNA-binding protein IKAROS family zinc finger 1 (IKZF1) is a zinc finger containing transcription factor that is encoded in 8 exons on chromosome 7 (7p12.2). IKZF1 functions upon homodimerization and acts as a chromatin remodeling protein involved in several chromatin remodeling complexes, such as nucleosome-remodeling and histone deacetylation (NuRD). 5 Alternative splicing of IKZF1 pre-mRNA gives rise to several isoforms. 6 The functional differences among the various isoforms of IKZF1 are mostly due to alterations of zinc finger structures required for DNA binding (4 zinc fingers in the N-terminal domain) or protein-protein interactions (2 zinc fingers in the C-terminal domain). 6, 7 Some of these splice variants lack the ability to properly bind DNA and act as dominant-negative repressors when dimerized with functional isoforms.
Loss of Ikzf1 function in mice homozygous for an Ikzf1 null allele or homozygous for a dominant-negative isoform of Ikzf1 results in an early arrest of lymphoid differentiation with lack of Tand B-lymphocytes and NK cells, as well as their earliest identifiable progenitors. 8, 9 In heterozygous Ikzf1 mutant mice, lymphocytes appear normal right after birth, but proliferation increases and differentiation arrest occurs rapidly, leading to the development of leukemia and lymphoma within three months after birth. 10 In humans, heterozygous loss of IKZF1 is found in 15% of B-cell precursor ALL (BCP-ALL) patients; in 70-80% of BCR/ABL1 (t(9;22)(q34;q11)) positive BCP-ALL patients and in 33%
of BCR/ABL1 negative BCP-ALL patients. [11] [12] [13] [14] [15] In BCR/ABL1 ALL patients, heterozygous loss of IKZF1 associates with a poor clinical outcome. In T-ALL heterozygous loss of IKZF1 is found in only 4%, but it remains unclear if this has any prognostic value. 11, 12 While the role of IKZF1 in lymphoid differentiation and ALL is firmly established, the role of IKZF1 in myeloid differentiation is less clear. However, there are some strong indications that IKZF1 is also involved in myeloid differentiation. In early myeloid progenitors, loss of IKZF1 function prolongs cell survival. 16 During erythropoiesis, IKZF1 supports survival of the erythroid lineage, and promotes erythrocyte differentiation at the expense of granulocyte and monocyte differentiation. [17] [18] [19] In early megakaryopoiesis IKZF1 represses differentiation by inhibiting genes associated with the NOTCH pathway and later on in differentiation towards megakaryocytes by controlling transcriptional regulators, such as GATA1 and RUNX1. 18, 20 Although IKZF1 is not required for the initial differentiation towards granulocytes and monocytes, IKZF1 represses differentiation of the basophilic granulocyte lineage and promotes early maturation and survival of the neutrophil granulocyte lineage. 17, 21, 22 In pediatric AML, monosomy 7 is found in only 4-5% of the patients. The 5-year OS and EFS of pediatric AML patients with monosomy 7 with or without additional cytogenetic or chromosomal aberrations are poor. 23 In adult AML, monosomy 7 is the most frequent single monosomy and has a similar poor 4-year overall survival as compared to other single autosomal monosomies. 24 Deletions of the short arm of chromosome 7, 7p (del7p) were recurrently found in adult de novo AML and secondary AML developed from myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). [25] [26] [27] Furthermore, 7p deletions were mapped to the IKZF1 locus and it was shown that loss of IKZF1 is acquired during the progression of MPN to secondairy AML, indicating that loss of IKZF1 contributes to the transformation from MPN to AML. 25 Together, these studies demonstrate that IKZF1 may play a role in myeloid differentiation and that loss of IKZF1 may contribute to myeloid oncogenesis. We therefore hypothesized that in pediatric AML patients with monosomy 7, IKZF1 may be an important player. In this study we analyzed the 7 powerful for small sample sizes. Bayesian false discovery rate (BFDR)<0.05 was considered statistically significant.
Results
Identification of IKZF1 deletions in pediatric AML
The cohort of newly diagnosed pediatric AML patients with available peripheral blood or bone marrow samples taken at initial diagnosis included in this study was previously described by Hollink et al (n=293; age, [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . 30 Of 293 well-characterized pediatric AML cases, 258 with available high quality DNA were analyzed with MLPA using 250ng of DNA. Cytogenetic aberrations in this group were representative for the frequencies seen in pediatric AML. 3, 32 In addition, 14 healthy control samples as negative controls, and one pediatric ALL sample known to harbor an IKZF1 deletion as positive control were analyzed. A succeeded MLPA was considered if all reference probes had a peak ratio between 0.75 and 1.25, except where a deletion or amplification of a reference probe could be explained by an aberration visible in the karyotype. The P335-B1;ALL-IKZF1 MLPA kit contains a probe in each of the 8 exons of IKZF1. All probes on chromosome 7 were analyzed individually, including reference probe 15370-L13762 located on 7q11.23 in P450 cytochrome oxidorectase (POR). Additional high-resolution array-CGH was performed on patients with an IKZF1 deletion detected by MLPA, but without knowledge of the existence of monosomy 7, and one additional case of monosomy 7 from which no material was available for MLPA analysis. Mutational screening of exon 4, 5 and 8 of IKZF1 was performed on the same cohort of 258 patients. This revealed no patient harboring a frameshift mutation, as described to be damaging in BCP-ALL. We did identify three patients with a heterozygous point mutation, p.V382M, which was predicted as tolerated by SIFT analysis and as benign by PoyPhen analysis, and p.G158S and p.L188P, which were predicted as deleterious by SIFT analysis and probably damaging by PolyPhen In total, 10 patients carried a heterozygous IKZF1 deletion as identified by MLPA, and one additional case as identified by array-CGH (Table 1) . From 258 patients, as determined by MLPA, 9
cases showed an IKZF1 deletion in all 8 exons, and 1 case showed a deletion of exon 1-4 with a normal peak ratio in the remaining exons (Figure 1 ). Four of these 10 cases showed a monosomy 7 with conventional karyotyping (Table 1) . Using array CGH on 7 patients, we identified 2 cases with monosomy 7 in patients with an unknown karyotype, 2 patients with monosomy 7 of whom the karyotype was (wrongly) defined as cytogenetically normal, and 3 cases with a focal 0.1-0.9Mb deletion of 7p12.2, where the IKZF1 gene is located ( Figure 2 , Table 1 ).
Combining the data gathered from MLPA, karyotype and array CGH, we defined 11 patients with an IKZF1 deletion, 8 of which showed complete loss of one copy of chromosome 7 (monosomy 7), and 3 of which showed a focal IKZF1 deletion. As shown in Figure 2 , patient #10 demonstrated a focal deletion (~0.1Mb) including exon 1-4 of IKZF1. The focal deletion in patient #2 included the IKZF1 gene and part of the C7orf72 gene (~0.3Mb), whereas patient #3 showed a focal deletion (~0.9Mb) including the IKZF1 gene and the genes for VWC2, ZPBP, C7orf72 and DDC. Together, these results map the deletions in these patients to the IKZF1 gene locus as the common deleted region.
Characteristics of IKZF1 deleted cases in pediatric AML
IKZF1 deleted cases did not differ significantly from the other pediatric AML cases concerning age at diagnosis (median age 9.1 years, range 0.7-14.1, compared to 9.5 years, range 0. 34 To ensure the included cases were AML patients and not patients with a mixed ALL and AML phenotype we used a previously defined AML vs ALL classifier. 35 As shown in Figure 3 , patients with focal IKZF1 deletions (dark green triangles) and patients with monosomy 7 (light green squares) clustered amongst the other AML patients (red circles) and away from the ALL patients (blue circles), based on the expression signatures of the AML-specific genes ( Figure 3A ), the ALLspecific genes ( Figure 3B ) and the combined AML/ALL-specific genes ( Figure 3C ). This indicates that the IKZF1 haploinsufficient AML cells of included patients indeed displayed pure AML cell gene expression profiles. Only of one of the three patients with a focal IKZF1 deletion immunophenotypical data was available (patient #2). This patient was classified as PML/RARA-negative AML FAB M3V
(TdT-/MPO+/cyCD79a-/CD34+/HLADR+/CD19-/CD10-/CD7+/CD13+/CD33+).
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Similarity between gene expression profiles of monosomy 7 and focal IKZF1 deleted cases
Loss of IKZF1 function, a well-known tumor inducing event in ALL, is conceivably one of the reasons for the recurrent heterozygous loss of chromosome 7, as this would include losing the IKZF1 locus on 7p12.2. We hypothesized that, if loss of IKZF1 would be one of the driving leukemic events in monosomy 7, the gene expression signature of monosomy 7 AML cells may resemble those that only have a focal IKZF1 deletion. However, we anticipated that this similarity might be quite weak because of the heterogeneity across the samples in our cohort, both derived from somatic and germ line genetic variation and the small sample size of monosomy 7 and IKZF1 deleted cases. Therefore, we performed genome wide differential gene expression analyses using a robust Bayesian method implemented in the R-package ShrinkBayes. 31 Probe sets were limited to those targeting a unique genes or having a selectivity score of >0.8 (www.geneannot.com). Further statistical analyses were performed in R, version 3.0.0. R scripts are available upon request. We first compared gene expression profiles of monosomy 7 samples (n=8) to those of IKZF1-non-deleted samples (n=247). We detected 244 probe sets representing 198 genes differently expressed (BFDR<0.05) between these two groups ( Figure 4A ). As might be expected, a large proportion of these genes (44%) is located on chromosome 7, and is down-regulated ( Figure 4B , Supplementary Table 3) .
Next, we compared the mean differences in expression of these 198 genes in monosomy 7 samples (n=8) to those in samples with IKZF1 focal deletions (n=3) ( Figure 4C ). For non-chromosome 7 genes, highly significant positive correlation was observed in gene expression differences (r=0.50, p=3e-10). A less significant positive correlation (r=0.33, p=5e-4) was observed for chromosome 7 genes ( Figure 4B ). To further test that the correlation of gene expression changes between monosomy 7 and focal IKZF1 deletions is not based on chance, we performed a bootstrap analyses taking 3 random patients and comparing them to the 8 patients with monosomy 7. As shown in Figure 4D , none of 100,000
comparisons displays a correlation approaching a value of 0.5 found for the patients with focal IKZF1
deletions.
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We next asked which non-chromosome 7 genes were responsible for the similarity between monosomy 7 and focal IKZF1 deletion gene expression profiles. Genes that substantially contribute to the correlation between monosomy 7 and IKZF1-only deleted gene expression differences are up-regulated in both groups ( Figure 4C ). Interestingly, the gene most clearly up-regulated in both monosomy 7 and IKFZ1-focal deleted samples was Hemogen (HEMGN), of which over-expression has been described to induce expansion of myeloid progenitor cells in a murine model. 36 Other genes with known pro-leukemic As up-regulation of HEMGN in IKZF1 hemizygous cells is relative to a fairly heterogeneous group, we stratified the control group in various more homogenous cytogenetic AML subgroups ( Figure   5A ). Median expression of HEMGN in each of those subgroups is clearly lower than in the IKZF1 deleted group. The same is true for FHL2, FZD6 and SETBP1 ( Figure 5B-D) , although it should be noted that FZD6 and SETBP1 are also highly expressed in patients with MNX1-ETV6 (t(7;12)). When excluding the patient harboring both an IKZF1 deletions and MNX1-ETV6 (t(7;12)), FZD6 and SETBP1 remain significantly higher expressed in the IKZF1-deleted cases compared to the other pediatric AML subgroups ( Figure 5E -F). These data indicate that up-regulation of these genes in IKZF1 deleted samples is not confounded by specific cytogenetic aberrations in pediatric AML.
Gene expression profiles of the IKZF1-deleted samples demonstrate enrichment in up-regulated GATA targets.
HEMGN, the gene most clearly up-regulated in both monosomy 7 and IKFZ1-focal deleted samples, is transcriptionally activated by GATA1 in the myeloid cell line K562. 37 We therefore investigated whether other genes that demonstrated a correlation between monosomy 7 and focally deleted IKFZ1 samples are 1 2 also GATA1 targets in K562. For this purpose, we used a GATA1 ChIP seq dataset in K562 cells. 38 From the 23 genes significantly up-regulated in the IKZF1-deleted samples, 11 genes had a GATA1 peak ratio larger than 25, indicating the gene being a GATA1 target ( Figure 6A ). Further analysis showed that whereas 13% of genes on our expression platform is a GATA1 target, 55% of genes that are up-regulated in IKZF1 deleted cases are GATA1 targets (p=3.5 e-7, Figure 6B ). While GATA transcription factors exhibit diverse functions in cellular proliferation, differentiation and gene regulation, only GATA1, GATA2, and GATA3 are expressed in developing blood cells and are critical for hematopoiesis. 39, 40 As shown in Figure 6C , GATA1 (p=0.07) and GATA3 (p=0.006) were up-regulated in the IKZF1-deleted samples (n=11) as compared to the rest (n=247). Direct interaction of IKZF1 with GATA proteins was previously demonstrated. 41 Together, these data emphasize the similarity in gene expression between monosomy 7 and focal IKZF1 deleted pediatric AML patients.
Discussion
In the last ten years, IKZF1 has been widely studied in the context of B-cell differentiation and acute lymphoblastic leukemia, both in adults and children. Accumulating evidence indicates that IKZF1 also plays a role in various stages of myeloid differentiation. So far, the best indication that loss of IKZF1 may contribute to myeloid leukemogenesis are deletions of the short arm of chromosome 7 associated with MPN-preceded secondary AML in adults, where the commonly deleted region is mapped to the IKZF1 locus. 25 Our finding of recurrent focal deletions that map to the IKZF1 gene locus in pediatric AML patients cells now provides additional support for a role for IKZF1 in myeloid leukemia.
Reduced IKZF1 gene function is a well-known recurrent event in BCP-ALL. In pediatric BCP-ALL, the overall frequency of focal IKZF1 deletions is around 15%, but is greatly enriched in BCR/ABL1
positive BCP-ALL at 70-80%. 15, 42 Here we report that focal IKZF1 deletions are also a recurrent event in 1 3
cytogenetic AML subgroups, we found 3 cases of a focal inactivating deletion of this gene (1.2%). In addition, three patients were identified with a single nucleotide variation leading to amino acid changes.
In contrast to mutations found in BCP-ALL, no frame shift mutations were detected, and the functional status of these SNV containing alleles remain to be determined.
In adult and pediatric BCP-ALL, in addition to focal IKZF1 deletions, monosomy 7 is a recurrent chromosomal aberration. In BCR/ABL1 positive BCP-ALLs, 16% (adult) and 13% (pediatric) of the cases of IKZF1 deletion can be attributed to monosomy 7. 14, 42 In pediatric AML, monosomy 7 is a recurrent chromosome loss, in particular in myeloproliverative diseases, such as juvenile myelomonocytic leukemia, progressed towards AML (40% of cases), but also in primary AML (4-5% of cases). 23, 43 In our pediatric de novo AML cohort, we found 8 cases (3.1%) of monosomy 7, consistent with earlier estimates. Across these monosomy 7 AML cases, we find various additional somatic mutations, most prominently PTPN11 (n=2) and NRAS mutations (n=2), adding up to half of cases presenting with an activated RAS pathway.
We hypothesized that in pediatric AML, as presumed in BCP-ALL, an important biological determinant for leukemogenesis in monosomy 7 patients is loss of the IKZF1 gene. 44 Evidence for this hypothesis was obtained by comparing gene expression profiles of monosomy 7 and focal IKZF1 deletions. We found a statistically significant correlation on non-chromosome 7 genes. We attribute the changes in chromosome 7 genes to bystander effects of deletion of the entire chromosome 7, leading to a widespread reduction in chromosome 7 encoded genes, many of which can be assumed to be without much consequence to the leukemogenic process. In contrast, the effects on non-chromosome 7 genes can be expected to be more enriched for leukemia related changes in the genetic program due to loss of one or more chromosome 7 encoded driving oncogenic mutations. The similarity of gene expression signatures between AML cases with monosomy 7 and those with a focal IKZF1 deletion therefore suggests that IKZF1 is one of the driving oncogenic events in monosomy 7 pediatric AML. Further data supporting this hypothesis is the observation that pediatric AML patients harboring monosomy 7 have a worse disease 1 4 outcome compared to those harboring 7q deletions. 23 Our findings may also explain the prevalence of monosomy 7 and focal IKZF1 deletions in mixed phenotype acute leukemia, as loss of IKZF1 now appears to be able to contribute to both acute lymphoblastic and myeloid leukemogenesis.
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Several genes up-regulated in both monosomy 7 and focal IKZF1 deleted AML cases are previously implicated in leukemogenesis. In a large cohort in adult BCP-ALL, comparison between focal IKZF1 deletions and IKZF1 wild-type cases revealed up-regulation of genes involved in cell cycle, JAK-STAT signaling and stem cell self-renewal. 45 We find up-regulation of HEMGN, a transcription factor implicated in myeloid self-renewal 36 , FHL2, enhanced expression of which leads to enhanced cell cycle entry, FZD6, that has shown to be involved in the pathologically reactivation of the Wnt/Fzd-mediated self-renewal signals that are enlisted during B-cell development and may be pathologically reactivated in the neoplastic transformation of mature B cells, and SETBP1, of which over-expression promotes the selfrenewal of myeloid progenitors. 46, 47, 48 It is interesting that similar cellular processes are affected in the IKZF1 deleted cases, while none of the genes deregulated in IKZF1 deleted adult BCP-ALL are found deregulated in this pediatric IKZF1 deleted AML cohort.
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Of note, we find a strong enrichment of myeloid GATA1 targets among genes commonly upregulated in focal IKZF1 deleted AML cases and monosomy 7 AML cases. This could be the confirmation that the genes commonly up-regulated in IKZF1 focal deletions and monosomy 7 did not present themselves by chance. However, it is tempting to speculate that IKZF1 haploinsufficiency in pediatric AML is influencing GATA transcription factor function. Supporting this idea, IKZF1 overexpression in transgenic mice represses GATA1 expression, implying that loss of IKZF1 function may increase GATA1 function.
21
Together, we find evidence for IKZF1 as a tumor suppressor gene in pediatric acute myeloid leukemia and suggest that IKZF1 deletion might be one of the driving events of monosomy 7 in various myeloid diseases.
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